EPAS1 and nonpapillary renal cell carcinoma: These studies demonstrate encouraging therapeutic efficacy of HIF-2α inhibition for ccRCC, and phase III clinical trials of Belzutifan are now ongoing (NCT04195750, NCT02974738).